Antifungal prophylaxis and treatment in patients with hematological malignancies.
نویسندگان
چکیده
Invasive fungal infection (IFI) is a serious and common complication in hematological patients. The risk is highest among acute leukemia patients undergoing induction chemotherapy and patients undergoing allogeneic hematopoietic stem-cell transplantation. Owing to the difficulty in diagnosing IFIs and the fatality rate associated with delayed treatment, antifungal prophylaxis and empirical antifungal therapy are standard management approaches. Novel agents, such as posaconazole and echinocandins, broaden our armamentarium against IFIs and improve patients' outcomes.
منابع مشابه
The expenditures related to the use of antifungal drugs in patients with hematological cancers: a cost analysis
OBJECTIVE The aim of this study is to analyze the expenditures related to the use of antifungal drugs in patients with hematological malignancies. METHODS In this retrospective study, the expenditures related to use of antifungal drugs for treatment of invasive fungal infections in patients with hematological malignancies between November 2010 and November 2012 were analyzed. Expenditures of ...
متن کاملFungal pathogens and primary antifungal prophylaxis in patients with hematological malignancies: one year experience.
BACKGROUND Febrile neutropenia (FN) is generally a complication of cancer chemotherapy in patients with hematological malignancies. OBJECTIVE To evaluate the febrile neutropenia episodes of hematological patients and their outcomes with respect to fungal pathogens, primary antifungal prophylaxis antifungal therapy. METHODS All consecutive patients older than 14 years of age and who develope...
متن کاملPrimary or secondary antifungal prophylaxis in patients with hematological maligancies: efficacy and damage
BACKGROUND Patients with hematological malignancies often develop febrile neutropenia (FN) as a complication of cancer chemotherapy. Primary or secondary antifungal prophylaxis is recommended for patients with hematological malignancies to reduce the risk of invasive fungal infection (IFI). This study retrospectively evaluated the efficacy and potential harm of administration of primary and sec...
متن کاملClinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients with hematological malignancies.
Advancements in early diagnosis and the introduction of effective agents have improved the rates of response of aspergillosis to primary antifungal therapy. These changes allow the subsequent continuation of cytotoxic chemotherapy and/or performance of hematopoietic stem cell transplantation in an increasing number of patients with hematological malignancies. These developments have increased i...
متن کاملAntifungal Prophylaxis in Immunocompromised Patients
Invasive fungal infections (IFIs) represent significant complications in patients with hematological malignancies. Chemoprevention of IFIs may be important in this setting, but most antifungal drugs have demonstrated poor efficacy, particularly in the prevention of invasive aspergillosis. Antifungal prophylaxis in hematological patients is currently regarded as the gold standard in situations w...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Expert review of anti-infective therapy
دوره 8 4 شماره
صفحات -
تاریخ انتشار 2010